Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-08-14 02:02 UTC

BIOMED PULSE

Daily Briefing on Longevity, Viruses & New Cures

August 14, 2026 | Edition #266

⚡ TL;DR

The Bundibugyo virus disease (Ebola) outbreak in DRC and Uganda has now surpassed 2,100 confirmed cases and 828 deaths as of July 15, making it the most consequential active outbreak on the planet right now. [1]

The overall mood is RED ALERT on hemorrhagic fever, cautious on food safety, and quietly optimistic on aging biology.

🦠 OUTBREAKS & VIRUSES

BUNDIBUGYO EBOLA - DRC AND UGANDA (CRITICAL)

  • As of July 15, 2026, cumulative confirmed cases reached 2,124 with 828 deaths in the DRC; cross-border transmission to Uganda remains active and sustained. [1]
  • The August 1 WHO Disease Outbreak News update confirms the outbreak has expanded well beyond its origin in Mongbwalu Health Zone, Ituri Province, spreading across multiple provinces over two months. [2]
  • CDC mobilized an international response beginning May 17, activated enhanced airport screening at Washington-Dulles International Airport on May 21, and expanded screening to Atlanta-Hartsfield on May 23. [3] [4]
  • The WHO classified the causative agent as Bundibugyo virus (BVD), a distinct Ebola species first identified in Uganda in 2007, with a case fatality ratio among confirmed cases tracking above 35 percent. [5] [6]

ANDES HANTAVIRUS - M/V HONDIUS CRUISE SHIP (MULTI-COUNTRY)

  • WHO's fifth Disease Outbreak News report (July 2, 2026) on the M/V Hondius cluster confirms the pathogen as Andes hantavirus (ANDV), which causes hantavirus cardiopulmonary syndrome; ANDV is the only hantavirus with documented person-to-person transmission. [7]
  • CDC's June 24 transcript update notes the agency continues active monitoring of passengers and crew who disembarked before containment measures were in place. [8]

MPOX RECOMBINANT STRAIN - GLOBAL

  • WHO reported in February 2026 that two cases of a recombinant MPXV strain combining genomic elements of clade Ib and clade IIb have been documented; recombination occurred when both strains co-infected the same individual. [9]
  • Recombination is a known natural process but is being closely monitored because clade Ib carries higher severity and IIb has shown broader human-to-human transmissibility. [9]
  • The first clade I mpox case in the United States was confirmed in California in November 2024, underscoring the U.S. exposure risk. [10]

CYCLOSPORA - TACO BELL / ICEBERG LETTUCE (MULTI-STATE)

  • As of July 17, 2026, CDC linked 1,644 Cyclospora infections across five states to shredded iceberg lettuce served at Taco Bell locations; the outbreak subsequently expanded to four additional states by July 24.
  • Cyclospora cayetanensis is a parasitic pathogen; infection causes prolonged, relapsing watery diarrhea and is not transmitted person to person.

SALMONELLA - JALAPEÑOS (ACTIVE)

  • CDC issued a food safety alert on August 5, 2026 warning of a multistate Salmonella outbreak linked to jalapeños.

NIPAH VIRUS - KERALA, INDIA

  • On June 11, 2026, Kerala State Health Department confirmed one laboratory-confirmed case of Nipah virus (NiV) infection in Kozhikode district in an adult male who developed neurological symptoms beginning May 30.
  • NiV has a case fatality ratio of 40 to 75 percent and no licensed treatment; the Kozhikode district has experienced prior NiV spillover events from Pteropus fruit bat reservoirs.

YELLOW FEVER - AMERICAS AND AFRICA

  • From January 1 to May 26, 2026, six countries reported 79 human infections with yellow fever; transmission activity that surged in the Americas in 2025 has continued into 2026.

WEST NILE VIRUS - UNITED STATES

  • CDC flagged an early West Nile virus season with record case counts in a July 1, 2026 alert coinciding with the Independence Day holiday weekend.

AVIAN INFLUENZA A(H9N2) - ITALY

  • Italy notified WHO on March 21, 2026 of a human A(H9N2) case in an adult male returning from Senegal; next-generation sequencing confirmed the subtype; the individual had no known poultry exposure in Italy.
  • H9N2 circulates widely in poultry across Asia and Africa and has served as a genetic donor in the emergence of pandemic-risk strains including H7N9.

MEASLES - BANGLADESH AND GLOBAL

  • WHO reported on April 23, 2026 that Bangladesh notified 19,161 suspected measles cases and 2,897 laboratory-confirmed cases spread across 58 of 64 districts nationwide.
  • Global context: 10.3 million people were infected with measles worldwide in 2023, a surge driven by pandemic-era vaccination gaps.
  • In the United States, CDC reinforced its national measles response through state collaboration as of March 9, 2026, following two deaths in Texas in early 2025.

🧬 LONGEVITY & AGING

CELLULAR SENESCENCE IN OSTEOARTHRITIS - DUAL ANTIOXIDANT AND EPIGENETIC APPROACH

  • A study published July 31, 2026 in Bioactive Materials describes a dual-modal strategy combining antioxidant and epigenetic agents to break the self-perpetuating senescence cycle in osteoarthritis cartilage, addressing both oxidative stress and pro-inflammatory SASP (senescence-associated secretory phenotype) simultaneously.
  • Cellular senescence is a state in which damaged cells stop dividing but remain metabolically active, releasing inflammatory signals that accelerate tissue aging; targeting this cycle is a central goal of geroscience.

PUNICALAGIN AND BONE STEM CELL SENESCENCE

  • Research published July 25, 2026 in Regenerative Therapy found that punicalagin, a polyphenol from pomegranate, alleviates senile osteoporosis in animal models by inhibiting senescence in bone mesenchymal stem cells via activation of the NRF2/HO-1 antioxidant pathway, preserving their capacity to generate new bone.
  • This pathway is a key regulator of cellular defense against oxidative damage, which accumulates in aging tissue.

TELOMERE REPAIR IN CANCER AND AGING CELLS

  • A study in the journal Nucleus (July 23, 2026) examined repair and misrepair of telomeric DNA in cancer cells treated with doxorubicin, finding dynamic interactions with PML nuclear bodies and lamin B1 that influence whether cells undergo proper senescence or acquire genomic instability.
  • Telomere shortening is one of the nine hallmarks of aging; faulty repair can accelerate cell aging or promote malignancy.

p16-INK4A ANTIBODY VALIDATION - SENESCENCE BIOMARKER RELIABILITY

  • A paper in Islets (July 21, 2026) flags the critical importance of antibody validation when detecting p16-INK4A, a canonical senescence marker, by immunohistochemistry in pancreatic tissue, warning that poorly validated antibodies may produce false signals that misrepresent the tissue's true senescent burden.
  • p16-INK4A accumulation is widely used in aging research as a proxy for cellular senescence load in vivo.

LYSOSOMAL AMPK ACTIVATION FOR METABOLIC LIVER DISEASE

  • Research published July 12, 2026 in Bioactive Materials reports that targeting the ROAM1 protein with UDP-GlcNAc nanosheets selectively activates lysosomal AMPK, resolving metabolic dysfunction-associated steatotic liver disease (MASLD) in preclinical models.
  • AMPK (AMP-activated protein kinase) is a master energy sensor whose lysosomal activation suppresses lipid accumulation and inflammation, two drivers of metabolic aging.

POSITIVE LIFE ORIENTATION AND BLOOD PRESSURE IN AGING COHORTS

  • A Finnish two-generational cohort study published August 7, 2026 in Blood Press found that positive life orientation is independently associated with lower blood pressure in older adults, with the association holding across cohorts born 20 years apart, suggesting it reflects a durable psychological aging buffer.

STATIN DEPRESCRIBING IN ADULTS OVER 75 - SAGA/SITE TRIAL

  • The SAGA/SITE multicenter open-label non-inferiority randomized trial, published in Lancet Healthy Longevity, assessed discontinuation of statins for primary prevention of atherosclerotic cardiovascular disease in adults aged 75 years or older, a population where net benefit is debated due to competing mortality risks.
  • An accompanying editorial in Lancet Healthy Longevity by Arya Nezhad and colleagues argues for shifting the default conversation around statin continuation in older adults rather than treating continuation as unquestionable.

METFORMIN PLUS LIFESTYLE INTERVENTION FOR PHYSICAL FUNCTION IN OLDER ADULTS WITH OBESITY (DEMFOS TRIAL)

  • The DEMFOS randomized controlled trial, published in Lancet Healthy Longevity, tested metformin added to lifestyle intervention on physical function outcomes in older adults with obesity; investigators include Villareal DT and colleagues at institutions including Baylor.
  • An accompanying editorial by Witham MD and McDonald C cautions against inflated expectations for adjunctive metformin in addressing obesity and frailty in older people, noting effect sizes were modest.

EPIGENETIC AGING IN DOGS - DIET SIGNALS

  • A pilot study published August 5, 2026 in Veterinary Record Open found that switching dogs to a minimally processed, human-grade diet significantly altered epigenetic aging clock readings, raising the possibility that dietary processing level - independent of macronutrient content - modulates biological aging rate.

💊 NEW CURES & APPROVALS

ORZEYFUL (OVEPOREXTON) - TAKEDA PHARMACEUTICALS USA

  • Takeda Pharmaceuticals USA received an original NDA approval (NDA 220860) for Orzeyful, whose active ingredient is oveporexton, a compound acting on the orexin system involved in wake-sleep regulation; the filing category is ORIG AP.
  • Oveporexton is an orexin-2 receptor agonist being developed for narcolepsy type 1, a condition involving orexin neuron loss; orexin deficiency is also being studied in the context of age-related sleep fragmentation.

INPEFA (SOTAGLIFLOZIN) - LEXICON PHARMACEUTICALS

  • Lexicon Pharmaceuticals received a supplemental approval (SUPPL AP) for Inpefa (NDA 216203), whose active ingredient is sotagliflozin, a dual SGLT1/SGLT2 inhibitor; SGLT2 inhibitors have demonstrated cardiovascular and renal protective effects relevant to aging-associated comorbidities.

TRYVIO (APROCITENTAN) - IDORSIA

  • Idorsia received a supplemental approval (SUPPL AP) for Tryvio (NDA 217686), active ingredient aprocitentan, an endothelin receptor antagonist approved for resistant hypertension; endothelin pathway dysregulation contributes to vascular stiffening in aging.

IQIRVO (ELAFIBRANOR) - IPSEN

  • Ipsen received a supplemental approval (SUPPL AP) for Iqirvo (NDA 218860), active ingredient elafibranor, a dual PPAR-alpha/delta agonist approved for primary biliary cholangitis (PBC), a chronic autoimmune liver disease more prevalent in older adults.

SAPHNELO (ANIFROLUMAB-FNIA) - ASTRAZENECA

  • AstraZeneca AB received a supplemental approval (SUPPL AP) for Saphnelo (BLA 761123), active ingredient anifrolumab-fnia, a type I interferon receptor antagonist for systemic lupus erythematosus (SLE).

XOLAIR (OMALIZUMAB) - GENENTECH

  • Genentech received a supplemental approval (SUPPL AP) for Xolair (BLA 103976), active ingredient omalizumab, an anti-IgE monoclonal antibody used in allergic asthma and chronic urticaria.

KRYSTEXXA (PEGLOTICASE) - HORIZON PHARMA

  • Horizon Pharma received a supplemental approval (SUPPL AP) for Krystexxa (BLA 125293), active ingredient pegloticase, a PEGylated recombinant uricase for chronic refractory gout, a condition whose prevalence rises sharply with age.

🧪 CLINICAL TRIALS

AMYLOID PET IN BALTIMORE LONGITUDINAL STUDY OF AGING (NCI/NIH)

  • NCT07099053 is enrolling participants from the Baltimore Longitudinal Study of Aging to track amyloid protein accumulation in the brain over time using PET imaging, aiming to identify pre-symptomatic cognitive decline trajectories in aging individuals.

PRKN AND PINK1 PARKINSON DISEASE NATURAL HISTORY (NIH)

  • NCT07613112 is a longitudinal natural history protocol for early-onset Parkinson disease linked to PRKN and PINK1 gene variants; these mitochondrial quality-control genes are central to understanding mitophagy impairment in both familial and sporadic aging-related neurodegeneration.

SATRALIZUMAB IN DUCHENNE MUSCULAR DYSTROPHY (ROCHE)

  • NCT06450639 is assessing efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab, a humanized anti-IL-6 receptor monoclonal antibody, in ambulatory and non-ambulatory participants with DMD aged 8 to under 18 years receiving corticosteroids; IL-6 pathway targeting intersects with both muscle aging and inflammatory degeneration.

ITEPEKIMAB (ANTI-IL-33) FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS - PHASE 3 (SANOFI/REGENERON)

  • NCT07484230 is a randomized, multicenter, double-blind Phase 3 study evaluating two dosing regimens of itepekimab monotherapy in Japanese adults aged 18 or older with inadequately controlled chronic rhinosinusitis with nasal polyps; IL-33 is an upstream alarmin driving type 2 airway inflammation.

EARLY METABOLIC EFFECTS OF ANTIRETROVIRAL DRUGS - HIV AND METABOLIC AGING (NIH)

  • NCT05652478 is a Phase 2 randomized study examining early metabolic effects of integrase strand transfer inhibitors (INSTIs) in healthy volunteers, targeting weight gain and metabolic dysregulation associated with long-term HIV treatment, which accelerates several aging phenotypes.

AUTOLOGOUS T CELLS EXPRESSING NEOANTIGEN TCRs FOR HEMATOLOGIC MALIGNANCIES (NIH)

  • NCT06904066 is testing personalized T cells transduced with retroviral vectors expressing participant-specific neoantigen T cell receptors in leukemias with TP53 or RAS mutations, an approach directly relevant to immune senescence and age-related clonal hematopoiesis.

📢 PUBLIC HEALTH

CDC NEW DIRECTOR

  • Susan Monarez, Ph.D., was sworn in as CDC Director on July 31, 2026 by HHS Secretary Kennedy under the Make America Healthy Again agenda.

U.S. WHO WITHDRAWAL COMPLETED

  • The United States formally completed its withdrawal from WHO on January 22, 2026, citing COVID-19 failures, politicization, and a stated shift to bilateral health efforts; WHO issued a formal statement of regret calling the withdrawal a risk to both U.S. and global health security.

TIMOR-LESTE CERTIFIED MALARIA-FREE

  • WHO certified Timor-Leste malaria-free on July 23, 2025, crediting a concerted nationwide elimination effort launched shortly after the country's independence in 2002.

CDC FREE MIND CAMPAIGN - YOUTH SUBSTANCE USE

  • On August 5, 2026 CDC launched its Free Mind campaign providing teens with targeted resources on substance use and mental health, following data showing improvements in some teen mental health indicators alongside persistent risk.

PNEUMOCOCCAL VACCINE - AGE LOWERED TO 50

  • CDC Director endorsed the ACIP recommendation in October 2024 to lower the age for pneumococcal vaccination from 65 to 50 years old, reflecting updated evidence that invasive pneumococcal disease risk rises meaningfully in adults in their 50s.

DRUG OVERDOSE DEATHS - SHARP DECLINE

  • CDC provisional data released May 14, 2025 show a 27 percent decrease in drug overdose deaths in 2024, building on a nearly 24 percent decline reported in February 2025, the largest sustained reduction on record.

BIOMED PULSE is an informational digest only. Nothing here constitutes medical advice. Always consult a qualified healthcare provider before making any health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  2. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  3. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  4. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  5. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  6. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  7. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News
  8. Transcript - Update on CDC's Hantavirus Response - 6/24/26 — CDC Newsroom
  9. Mpox: recombinant virus with genomic elements of clades Ib and… — WHO Disease Outbreak News
  10. California confirms first clade I mpox case — CDC Newsroom

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260814-02-v55 · 2026-08-14 02:02 UTC · pulse.uzylab.com

Read next